Management ChangeJul 22, 2026, 04:32 PM
Serina Therapeutics Appoints Farrell Simon to Board of Directors
AI Summary
Serina Therapeutics, Inc. announced the appointment of Farrell Simon, Pharm. D., to its Board of Directors, effective immediately. Dr. Simon will also serve on the Board's Audit and Compensation Committees. With extensive experience in commercial strategy, business development, and investor engagement from his roles at Trevi Therapeutics and Pfizer, he is expected to be invaluable as Serina advances its SER-252 program and expands its POZ Platform™.
Key Highlights
- Serina Therapeutics appointed Farrell Simon, Pharm. D., to its Board of Directors.
- Dr. Simon will serve on the Board's Audit and Compensation Committees.
- He is currently Chief Commercial Officer at Trevi Therapeutics, Inc.
- Dr. Simon helped Trevi Therapeutics raise over $400 million in financing.
- He previously held senior commercial and strategic leadership roles at Pfizer for a decade.
- Serina is advancing its lead program, SER-252, for Parkinson's disease.
- The company utilizes its proprietary POZ Platform™ drug optimization technology.
Price Impact
More from SER